According to a new market research report published by SNS Insider, the global AI in Precision Medicine Market was valued at USD 1.80 billion in 2023 and is projected to reach USD 18.27 billion by 2032, growing at an exceptional CAGR of 29.37% during the forecast period of 2024–2032. This surge is driven by rapid advancements in artificial intelligence applications across healthcare, especially in oncology, genomics, drug development, and medical diagnostics.
Growth Drivers Fueling the AI in Precision Medicine Market
The growing demand for personalized healthcare solutions and the exponential increase in patient data are creating fertile ground for AI-powered technologies in precision medicine. Traditional approaches to diagnosis and treatment are being replaced by data-driven, patient-specific strategies that use AI to analyze genetic, phenotypic, and lifestyle data. Moreover, rising cancer prevalence and chronic diseases, the need for real-time clinical decision-making, and increasing investments from tech giants and startups are significantly propelling the growth of the AI in Precision Medicine Market.
Get a Free Sample Report of AI in Precision Medicine Market@ https://www.snsinsider.com/sample-request/6030
Cloud computing, increased access to electronic health records (EHRs), and improved AI training data are enabling AI algorithms to operate with higher precision and scalability. Key innovations such as deep learning and natural language processing are transforming how clinicians and researchers detect diseases, develop therapies, and personalize treatment plans.
Component Analysis: Software Segment Leads with 58% Market Share
In 2023, the software segment accounted for the largest share—58%—of the total market revenue. AI-based platforms are increasingly used for diagnostics, drug discovery, patient management, and predictive modeling. These tools empower clinicians with real-time, data-driven insights, improve decision-making, and streamline complex medical workflows.
Notable innovations in this space include:
IBM Watson Health, which continues to advance oncology-focused AI software.
Tempus AI, which recently introduced next-gen genomic sequencing analytics.
NVIDIA Clara and Microsoft Project InnerEye, which leverage AI in medical imaging and radiotherapy planning.
Technology Overview: Deep Learning Dominates with 49% Share
Deep learning technology remains a cornerstone in the AI precision medicine ecosystem, accounting for 49% of total market revenue in 2023. This technology supports medical imaging analysis, genetic data interpretation, and pathology diagnostics through highly accurate and scalable algorithms.
Key contributions include:
Google DeepMind’s AlphaFold, revolutionizing protein structure prediction.
PathAI, applying deep learning to improve pathology assessments.
NVIDIA’s MONAI framework, enhancing deep learning models in radiology.
Deep learning continues to expand its reach into genomics, where platforms like Illumina utilize AI to discover critical genetic mutations linked to disease outcomes.
Deployment Model: Cloud-Based Solutions Secure 69% Share
The cloud-based deployment segment led the market in 2023 with a commanding 69% share. The flexibility, scalability, and real-time capabilities of cloud-based AI platforms make them ideal for managing vast datasets including EHRs, genomic sequences, and imaging records.
Leading innovations:
NVIDIA Clara Parabricks, offering cloud-based genomic data processing.
Secure cloud infrastructures allowing real-time collaboration among healthcare providers, research centers, and pharmaceutical firms.
Cloud deployments reduce operational costs, enable faster clinical decisions, and ensure high data security, promoting rapid adoption.
Therapeutic Area: Oncology at the Forefront with 48% Revenue Share
With the rising global cancer burden, oncology emerged as the dominant therapeutic area, contributing 48% of total market revenue. AI is playing a pivotal role in transforming cancer care—from early detection to treatment selection—by analyzing imaging, genomic, and clinical data to personalize interventions.
Examples include:
IBM Watson for Oncology, providing AI-driven treatment guidance.
Paige AI, using deep learning in pathology image analysis for cancer detection.
AI-enhanced radiotherapy planning and predictive analytics, helping clinicians target tumors with improved accuracy.
The result is reduced treatment side effects, improved survival rates, and better outcomes.
Application Segment: Drug Discovery & Development Leads with 44%
The drug discovery and development segment led all applications with a 44% share, as AI tools are reshaping how new therapies are identified, tested, and brought to market. These tools speed up drug development cycles, optimize trial design, and reduce R&D costs.
Top innovators include:
BenevolentAI and Exscientia, developing AI-generated drug candidates.
AI-powered biomarker discovery, allowing the design of targeted therapies.
Platforms like Insilico Medicine’s PandaOmics, helping repurpose existing drugs based on AI analytics.
This convergence of AI with pharmaceutical R&D is creating faster, more effective, and patient-specific therapeutic options.
End-User Analysis: Healthcare Providers Drive 38% of Market Demand
Healthcare providers accounted for 38% of the global revenue in 2023, as hospitals and research institutions rapidly integrate AI to enhance clinical decision-making and streamline patient management. AI-enabled diagnostics, real-time predictive analytics, and integration with EHRs help clinicians offer highly personalized care.
Key players include:
GE Healthcare, offering AI-enhanced diagnostic imaging.
Telehealth platforms powered by AI, improving access to rural and underserved populations.
This growing ecosystem is reducing hospital readmissions and optimizing patient care delivery.
Need Any Customization Research on AI in Precision Medicine Market, Enquire Now@ https://www.snsinsider.com/enquiry/6030
Regional Insights: North America Leads; Europe Fastest Growing
North America held the largest share of the global market in 2023, accounting for approximately 46%, driven by a robust healthcare infrastructure, early technology adoption, and strong industry partnerships. Companies like IBM, Tempus, and NVIDIA are headquartered in the U.S., further consolidating the region’s leadership.
Meanwhile, Europe is the fastest-growing market, with a projected CAGR of 36.13%. The EU’s Horizon Europe Program, along with government initiatives in Germany, the UK, and France, is fostering AI integration in healthcare. Research centers across Europe are leveraging AI for radiology, genomics, and pathology, further boosting regional growth.
Key Players in the Global AI in Precision Medicine Market
Prominent companies driving innovation include:
BenevolentAI, Tempus AI, Exscientia, PathAI, NVIDIA, Flatiron Health, Paige AI, Owkin, Verge Genomics, Insilico Medicine, Guardant Health, Grail, Foundation Medicine, Deep Genomics, Proscia, Predictive Oncology, Nucleai, Zephyr AI, Densitas, Valar Labs, and Berg LLC.
Recent Developments
February 2025: Tempus AI reported a quarterly revenue of USD 200.7 million but faced a 17% drop in stock due to increased operating costs tied to expanding testing capacity and sales infrastructure.
November 2023: Exscientia entered a strategic alliance with Tempus to leverage multimodal data for biomarker-focused drug development.
January 2025: BenevolentAI announced a potential re-listing in London by 2026 after organizational restructuring and strategic refocus on core AI capabilities.
Conclusion
The global AI in Precision Medicine Market is undergoing transformative growth as artificial intelligence redefines the future of personalized healthcare. From revolutionizing cancer care to accelerating drug discovery and enhancing diagnostic accuracy, AI is central to creating more efficient, data-driven medical ecosystems. With continued technological innovation, increasing investments, and widespread healthcare adoption, the market is poised for exponential expansion through 2032.
Buy a Single-User PDF of AI in Precision Medicine Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6030
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
